Mindset Pharma Inc. and PharmAla Biotech Holdings Inc. announced that PharmAla has completed the first sale of a quantity of Mindset's cGMP (i.e. pharmaceutical grade) psilocybin under their exclusive sales agreement. The psilocybin is being purchased by Reset Mind Sciences Limited, a Western Australian based company focused on psychedelic medicines, and a subsidiary of ASX listed Little Green Pharma. Reset recently received human research ethics committee approval for a clinical trial investigating psilocybin assisted psychotherapy protocols for patients with treatment resistant major depressive disorder.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.22 CAD | 0.00% | +2.33% | +57.14% |
Apr. 19 | Pharmala Biotech Completes $750,000 Private Placement, Debt Settlement | MT |
Apr. 19 | Pharmala Biotech Holdings Inc. announced that it has received CAD 0.75 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
+57.14% | 13.97M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- MDMA Stock
- News Pharmala Biotech Holdings Inc.
- Mindset Pharma Inc. and PharmAla Biotech Holdings Inc. Complete First Sale of Pharmaceutical Grade Psilocybin into Growing Australian Market Via Sales Partnership